Evidence map›Paper›PMID 25678772›Full record

ReviewDrug design, development and therapy2015

Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin.

Hongyu Wang, Jinbo Liu, Hongwei Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hongyu WangDepartment of Vascular Medicine, Peking University Shougang Hospital, Beijing, People's Republic of China.
Jinbo LiuDepartment of Vascular Medicine, Peking University Shougang Hospital, Beijing, People's Republic of China.
Hongwei ZhaoDepartment of Vascular Medicine, Peking University Shougang Hospital, Beijing, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2DM) has become a worldwide health problem, and the rate of it is growing greatly in the People's Republic of China every year. T2DM could cause macrovascular and microvascular complications that lead to an increase in arterial wall thickness, endothelial dysfunction, calcification, and - finally - to an increase in arterial stiffness and arterial dysfunction. Alogliptin, a new selective inhibitor of dipeptidyl peptidase 4, has shown its great antihyperglycemia effect in T2DM patients. The clinical trial data from the People's Republic of China was similar to other global and Asian trials. This could provide some choice for clinical physicians to the treatment of T2DM.

Indexed as

Asian PeopleAnimalsArteriesChinaDiabetes Mellitus, Type 2Diabetic AngiopathiesDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsHumansPiperidinesRisk FactorsTreatment OutcomeUracilVascular StiffnessalogliptinDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsDPP4 protein, humanPiperidinesUracilalogliptinarterial functionPeople’s Republic of Chinatype 2 diabetes mellitus

Identifiers

PMID25678772
PMCPMC4322603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.